Stresscopin-related peptide - RELIEF THERAPEUTICS Holding
Latest Information Update: 21 Sep 2023
At a glance
- Originator mondoBIOTECH
- Developer RELIEF THERAPEUTICS Holding
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 21 Sep 2023 Discontinued - Preclinical for Vascular disorders in Switzerland (unspecified route)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Vascular-disorders in Switzerland
- 15 Sep 2016 Stresscopin-related peptide - Relief Therapeutics is available for licensing as of 15 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/